LCA-0321 is a LYTAC degrader designed to specifically bind and rapidly deplete anti-TSHR autoantibodies, the underlying cause of Graves’ disease and its extrathyroidal manifestations, including ...
EmblemHealth, one of the nation's largest not-for-profit health insurers, today announced the appointment of Dr. Daniel Knecht as its new Chief Medical Officer. As CMO, Dr. Knecht will lead the health ...
Syantra, Inc., a precision biotechnology company revolutionizing cancer detection and treatment, proudly announces Dr. Edith A. Perez as chair and Dr. Maria Theodoulou and Dr. Adetunji Toriola as ...